HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
25 sources retrieved Β· Most recent: April 2026 Β· Index updated 15 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
SMARCE1
SWI/SNF related BAF chromatin remodeling complex subunit E1
Chromosome 17 Β· 17q21.2
NCBI Gene: 6605Ensembl: ENSG00000073584.21HGNC: HGNC:11109UniProt: Q969G3
233PubMed Papers
22Diseases
0Drugs
76Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedHub Gene
RESEARCH IMPACT
TrendingVariant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
protein-containing complexprotein bindingN-acetyltransferase activitynuclear receptor bindingCoffin-Siris syndromefamilial meningiomahereditary neoplastic syndromeInherited cancer-predisposing syndrome
✦AI Summary

SMARCE1 encodes a core subunit of SWI/SNF chr17 remodeling complexes that regulates transcription through ATP-dependent alteration of DNA-nucleosome topology 1. SMARCE1 belongs to both the neural progenitor-specific (npBAF) and neuron-specific (nBAF) complexes, which undergo compositional switching during neural development to support the transition from proliferating stem cells to differentiated neurons. The protein functions in transcriptional activation and repression through interactions with histone acetyltransferases and corepressor complexes like CoREST. Mechanistically, SMARCE1 loss induces EGFR expression in lung cancer and confers resistance to MET and ALK inhibitors, suggesting tumor suppressor functions 2. Clinically, SMARCE1 mutations cause Coffin-Siris syndrome (CSS), a rare multisystem autosomal dominant disorder characterized by intellectual disability, dysmorphic features, and organ anomalies 13. Adult CSS patients with SMARCE1 variants display increased obesity, visual impairment, scoliosis, and moderate intellectual disability 3. SMARCE1 variants also associate with meningiomatosis, where they occur in approximately 8% of patients and represent potential targets for molecular testing and therapeutic stratification 45. Additionally, SMARCE1 alterations appear in gastric and uveal melanomas, suggesting broader roles in cancer biology 67.

Sources cited
1
SMARCE1 mutations cause Coffin-Siris syndrome; SMARCE1-related variants associated with developmental delay and organ-related complications
PMID: 34205270
2
Adult CSS cohort with SMARCE1 variants shows increased obesity, visual impairment, scoliosis, and moderate intellectual disability
PMID: 38117302
3
SMARCE1 loss induces EGFR expression and confers resistance to MET and ALK inhibitors in lung cancer through chromatin remodeling
PMID: 25656847
4
SMARCE1 variants identified in ~8% of meningiomatosis patients; targeted NGS useful for differential diagnosis of meningiomatosis
PMID: 29409008
5
SMARCE1 alterations are recurring molecular aberrations in meningiomas with potential clinical significance
PMID: 39577862
6
SMARCE1 expression and co-amplification with ERBB2 occurs in gastric cancer with potential implications for treatment
PMID: 36916408
7
SMARCE1 mutations identified among genetic alterations in uveal melanoma
PMID: 34564968
Disease Associationsβ“˜22
Coffin-Siris syndromeOpen Targets
0.75Strong
familial meningiomaOpen Targets
0.72Strong
hereditary neoplastic syndromeOpen Targets
0.55Moderate
Inherited cancer-predisposing syndromeOpen Targets
0.55Moderate
neurodegenerative diseaseOpen Targets
0.53Moderate
meningiomaOpen Targets
0.52Moderate
asthmaOpen Targets
0.40Weak
bile duct carcinomaOpen Targets
0.37Weak
carcinoma of liver and intrahepatic biliary tractOpen Targets
0.37Weak
Coffin-Siris syndrome 1Open Targets
0.37Weak
colorectal adenocarcinomaOpen Targets
0.37Weak
Endometrial Endometrioid AdenocarcinomaOpen Targets
0.37Weak
familial multiple meningiomaOpen Targets
0.37Weak
Hepatobiliary NeoplasmOpen Targets
0.37Weak
Transitional MeningiomaOpen Targets
0.37Weak
Tessier cleftOpen Targets
0.34Weak
non-small cell lung carcinomaOpen Targets
0.29Weak
hepatocellular carcinomaOpen Targets
0.28Weak
endometrial carcinomaOpen Targets
0.28Weak
lung adenocarcinomaOpen Targets
0.28Weak
Coffin-Siris syndrome 5UniProt
MeningiomaUniProt
Pathogenic Variants76
NM_003079.5(SMARCE1):c.715C>T (p.Arg239Ter)Pathogenic
Familial meningioma|not provided|Hereditary cancer-predisposing syndrome
β˜…β˜…β˜†β˜†2026β†’ Residue 239
NM_003079.5(SMARCE1):c.587del (p.Phe196fs)Pathogenic
Familial meningioma
β˜…β˜…β˜†β˜†2025β†’ Residue 196
NM_003079.5(SMARCE1):c.369+2_369+5delLikely pathogenic
Familial meningioma
β˜…β˜…β˜†β˜†2025
NM_003079.5(SMARCE1):c.275dup (p.Leu93fs)Pathogenic
Hereditary cancer-predisposing syndrome|Familial meningioma
β˜…β˜…β˜†β˜†2025β†’ Residue 93
NM_003079.5(SMARCE1):c.751C>T (p.Arg251Ter)Pathogenic
not provided|Familial meningioma|Hereditary cancer-predisposing syndrome
β˜…β˜…β˜†β˜†2025β†’ Residue 251
NM_003079.5(SMARCE1):c.624_627del (p.Ser208fs)Pathogenic
Familial meningioma|not provided|Coffin-Siris syndrome 5
β˜…β˜…β˜†β˜†2025β†’ Residue 208
NM_003079.5(SMARCE1):c.554del (p.Gly185fs)Pathogenic
Hereditary cancer-predisposing syndrome|Familial meningioma
β˜…β˜…β˜†β˜†2025β†’ Residue 185
NM_003079.5(SMARCE1):c.493G>T (p.Glu165Ter)Pathogenic
Familial meningioma|Hereditary cancer-predisposing syndrome
β˜…β˜…β˜†β˜†2024β†’ Residue 165
NM_003079.5(SMARCE1):c.314G>A (p.Arg105Gln)Pathogenic
not provided|Familial meningioma
β˜…β˜…β˜†β˜†2024β†’ Residue 105
NM_003079.5(SMARCE1):c.92del (p.Tyr31fs)Pathogenic
Familial meningioma
β˜…β˜…β˜†β˜†2024β†’ Residue 31
NM_003079.5(SMARCE1):c.472C>T (p.Arg158Ter)Pathogenic
Familial meningioma|Hereditary cancer-predisposing syndrome
β˜…β˜…β˜†β˜†2024β†’ Residue 158
NM_003079.5(SMARCE1):c.673C>T (p.Gln225Ter)Pathogenic
Hereditary cancer-predisposing syndrome|Familial meningioma
β˜…β˜…β˜†β˜†2023β†’ Residue 225
NM_003079.5(SMARCE1):c.237+1G>TPathogenic
Coffin-Siris syndrome 5
β˜…β˜…β˜†β˜†2023
NM_003079.5(SMARCE1):c.276G>C (p.Lys92Asn)Likely pathogenic
Coffin-Siris syndrome 5
β˜…β˜…β˜†β˜†2023β†’ Residue 92
NM_003079.5(SMARCE1):c.328G>T (p.Glu110Ter)Pathogenic
Familial meningioma|Hereditary cancer-predisposing syndrome
β˜…β˜…β˜†β˜†2022β†’ Residue 110
NM_003079.5(SMARCE1):c.313C>T (p.Arg105Ter)Pathogenic
Familial meningioma
β˜…β˜†β˜†β˜†2025β†’ Residue 105
NM_003079.5(SMARCE1):c.93_94del (p.Tyr31_Ser32delinsTer)Pathogenic
Familial meningioma
β˜…β˜†β˜†β˜†2025β†’ Residue 31
NM_003079.5(SMARCE1):c.816+1G>TPathogenic
Hereditary cancer-predisposing syndrome
β˜…β˜†β˜†β˜†2025
NM_003079.5(SMARCE1):c.775_784del (p.Phe259fs)Pathogenic
Hereditary cancer-predisposing syndrome
β˜…β˜†β˜†β˜†2025β†’ Residue 259
NM_003079.5(SMARCE1):c.285G>C (p.Glu95Asp)Likely pathogenic
Coffin-Siris syndrome 5
β˜…β˜†β˜†β˜†2025β†’ Residue 95
View on ClinVar β†—
Related Genes
H3-3BProtein interaction100%H3C12Protein interaction100%H2BC21Protein interaction100%H2BC17Protein interaction100%H2AC6Protein interaction99%H2BC4Protein interaction99%
Tissue Expression6 tissues
Brain
100%
Ovary
70%
Lung
49%
Liver
39%
Bone Marrow
25%
Heart
13%
Gene Interaction Network
Click a node to explore
SMARCE1H3-3BH3C12H2BC21H2BC17H2AC6H2BC4
PROTEIN STRUCTURE
Preparing viewer…
PDB7CYU Β· 2.55 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.32Highly Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.15 [0.08–0.32]
RankingsWhere SMARCE1 stands among ~20K protein-coding genes
  • #1,718of 20,598
    Most Researched233 Β· top 10%
  • #970of 5,498
    Most Pathogenic Variants76 Β· top quartile
  • #1,271of 17,882
    Most Constrained (LOEUF)0.32 Β· top 10%
Genes detectedSMARCE1
Sources retrieved25 papers
Response timeβ€”
πŸ“„ Sources
25β–Ό
1
PMID: 23556151
1.00
2
Genotype-Phenotype Correlations in 208 Individuals with Coffin-Siris Syndrome.
PMID: 34205270
Genes (Basel) Β· 2021
0.90
3
Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
PMID: 29409008
Neuro Oncol Β· 2018
0.80
4
Targeting and monitoring ovarian cancer invasion with an RNAi and peptide delivery system.
PMID: 38437557
Proc Natl Acad Sci U S A Β· 2024
0.76
5
Targeting SUMOylation promotes cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma.
PMID: 41193430
Nat Commun Β· 2025
0.72